[Helicobacter pylori eradication therapy in Korea].

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Helicobacter pylori (H. pylori) is known to be associated with many gastrointestinal diseases including peptic ulcer. In Korea, eradication of H. pylori is recommended for peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue lymphoma, and early gastric cancer. Standard triple therapy using proton pump inhibitor, clarithromycin, and amoxicillin and bismuth-containing quadruple therapy have been the main first-line and second-line therapy for H. pylori in Korea. Although eradication rate of second-line quadruple therapy remains similar to that of the past, the success rate of eradication with triple therapy has decreased with increasing antimicrobial resistance to H. pylori. There is no standard third-line therapy, and some regimens that incorporate levofloxacin, moxifloxacin, and rifabutin can be used. New regimens such as sequential or concomitant therapy are suggested as alternative treatment for H. pylori. We need more well designed randomized controlled studies to choose proper treatment for H. pylori infection.

Original languageEnglish
Pages (from-to)67-73
Number of pages7
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume58
Issue number2
Publication statusPublished - 2011 Dec 1

Fingerprint

Korea
Helicobacter pylori
Peptic Ulcer
Therapeutics
Rifabutin
Marginal Zone B-Cell Lymphoma
Levofloxacin
Bismuth
Clarithromycin
Proton Pump Inhibitors
Gastrointestinal Diseases
Amoxicillin
Helicobacter Infections
Gastric Mucosa
Stomach Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Helicobacter pylori eradication therapy in Korea]. / Kim, Seung Young; Jung, Sung Woo.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 58, No. 2, 01.12.2011, p. 67-73.

Research output: Contribution to journalReview article

@article{e22219c5519a4f4bb767bbbf9f5af991,
title = "[Helicobacter pylori eradication therapy in Korea].",
abstract = "Helicobacter pylori (H. pylori) is known to be associated with many gastrointestinal diseases including peptic ulcer. In Korea, eradication of H. pylori is recommended for peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue lymphoma, and early gastric cancer. Standard triple therapy using proton pump inhibitor, clarithromycin, and amoxicillin and bismuth-containing quadruple therapy have been the main first-line and second-line therapy for H. pylori in Korea. Although eradication rate of second-line quadruple therapy remains similar to that of the past, the success rate of eradication with triple therapy has decreased with increasing antimicrobial resistance to H. pylori. There is no standard third-line therapy, and some regimens that incorporate levofloxacin, moxifloxacin, and rifabutin can be used. New regimens such as sequential or concomitant therapy are suggested as alternative treatment for H. pylori. We need more well designed randomized controlled studies to choose proper treatment for H. pylori infection.",
author = "Kim, {Seung Young} and Jung, {Sung Woo}",
year = "2011",
month = "12",
day = "1",
language = "English",
volume = "58",
pages = "67--73",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "2",

}

TY - JOUR

T1 - [Helicobacter pylori eradication therapy in Korea].

AU - Kim, Seung Young

AU - Jung, Sung Woo

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Helicobacter pylori (H. pylori) is known to be associated with many gastrointestinal diseases including peptic ulcer. In Korea, eradication of H. pylori is recommended for peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue lymphoma, and early gastric cancer. Standard triple therapy using proton pump inhibitor, clarithromycin, and amoxicillin and bismuth-containing quadruple therapy have been the main first-line and second-line therapy for H. pylori in Korea. Although eradication rate of second-line quadruple therapy remains similar to that of the past, the success rate of eradication with triple therapy has decreased with increasing antimicrobial resistance to H. pylori. There is no standard third-line therapy, and some regimens that incorporate levofloxacin, moxifloxacin, and rifabutin can be used. New regimens such as sequential or concomitant therapy are suggested as alternative treatment for H. pylori. We need more well designed randomized controlled studies to choose proper treatment for H. pylori infection.

AB - Helicobacter pylori (H. pylori) is known to be associated with many gastrointestinal diseases including peptic ulcer. In Korea, eradication of H. pylori is recommended for peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue lymphoma, and early gastric cancer. Standard triple therapy using proton pump inhibitor, clarithromycin, and amoxicillin and bismuth-containing quadruple therapy have been the main first-line and second-line therapy for H. pylori in Korea. Although eradication rate of second-line quadruple therapy remains similar to that of the past, the success rate of eradication with triple therapy has decreased with increasing antimicrobial resistance to H. pylori. There is no standard third-line therapy, and some regimens that incorporate levofloxacin, moxifloxacin, and rifabutin can be used. New regimens such as sequential or concomitant therapy are suggested as alternative treatment for H. pylori. We need more well designed randomized controlled studies to choose proper treatment for H. pylori infection.

UR - http://www.scopus.com/inward/record.url?scp=84555170214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555170214&partnerID=8YFLogxK

M3 - Review article

C2 - 21873820

AN - SCOPUS:84555170214

VL - 58

SP - 67

EP - 73

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 2

ER -